SAPHYR Trial: Sarilumab’s Impact on Refractory Polymyalgia Rheumatica

EP: 1.Updates to Polymyalgia Rheumatica Care: Sarilumab Insights

Now Viewing

EP: 2.SAPHYR Trial: Sarilumab’s Impact on Refractory Polymyalgia Rheumatica

EP: 3.Key Patient Characteristics in the SAPHYR Trial

EP: 4.The Impact of Sarilumab on Patient Reported Outcomes

EP: 5.Polymyalgia Rheumatica: Achieving Sustained Remission

EP: 6.Updating Guidelines and Payer Access for Refractory Polymyalgia Rheumatica

EP: 7.SAPHYR Study Insights and Limitations

EP: 8.How the SAPHYR Trial Has Impacted Rheumatology Care

This is a video synopsis/summary of a Between the Lines involving Robert Spiera, M.D., and Dana McCormick, R.Ph.

Dana McCormick, R.Ph., and Robert Spiera, M.D., discuss the SAPHYR trial evaluating sarilumab for polymyalgia rheumatica. Focused on steroid-sparing efficacy, the trial targeted tough-to-treat patients, aiming for sustained remission over a year. The study, utilizing sarilumab, involved rapid steroid tapering and a placebo group on a standard taper. The goal was sustained remission by week 52, with stringent criteria including C-reactive protein normalization and no flares post week 14. Secondary outcomes included glucocorticoid dose, flare time and safety. Patient-reported quality-of-life assessments were crucial for this lesser-known disorder, aiding differentiation from other inflammations. Understanding the trial’s design and outcomes sheds light on sarilumab’s potential as a significant therapy. Such insights into effective treatments are vital for optimizing care and improving the lives of patients with polymyalgia rheumatica, a condition often misconstrued among inflammatory diseases.

This summary was AI-generated and reviewed by Managed Healthcare Executive^® staff.